The present application relates generally to enhancing cerebral blood flow, and specifically to stimulation of the sphenopalatine ganglion (SPG).
International Patent Application WO 2001/085094 to Shalev et al. describes apparatus for modifying a property of a brain of a patient, including one or more electrodes, adapted to be applied to a site selected from a group of sites consisting of: a sphenopalatine ganglion (SPG) of the patient and a neural tract originating in or leading to the SPG. A control unit is adapted to drive the one or more electrodes to apply a current to the site capable of inducing an increase in permeability of a blood-brain barrier (BBB) of the patient, (b) a change in cerebral blood flow of the patient, and/or (c) an inhibition of parasympathetic activity of the SPG. Other embodiments are also described.
U.S. Pat. No. 9,233,245 to Lamensdorf et al. describes a method for treating a subject, including applying electrical stimulation to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve. The stimulation is configured to excite nervous tissue of the site at a strength sufficient to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow (CBF) of the subject, and a release of one or more neuroprotective substances, and insufficient to induce a significant increase in permeability of a blood-brain barrier (BBB) of the subject. Other embodiments are also described.
In accordance with some applications of the present invention, a system and method are provided for increasing cerebral blood flow (CBF) of a patient in cardiac arrest or in an acute post-cardiac arrest phase. For some applications two or more electrodes are coupled to tissue of a patient in cardiac arrest or in an acute post-cardiac arrest phase and CBF of the patient is increased by activating a power source to drive the electrodes to apply current to a sphenopalatine ganglion (SPG) of the patient. For some applications, the SPG stimulation is applied after a defibrillator is used to apply an electric charge to a heart of the patient.
For some applications, an SPG stimulating device is placed in a nose of the patient for nasal-only stimulation of the SPG. The SPG stimulation device typically has a sheath, a nasal stabilizer disposed around the sheath for stabilizing the device with respect to a nostril of the patient, an electrode mount slidably disposed within the sheath, and at least one electrode coupled to the mount and deployable out of the sheath (e.g., by pushing the electrode mount distally or by pulling the sheath proximally) in order to position the electrode to stimulate the SPG. The SPG stimulating device may include a camera configured to facilitate navigation of the sheath toward the SPG, and/or a sensor configured to sense a physiological response of the patient to stimulation of the SPG.
Alternatively, for some applications, the electrodes of the SPG stimulating device are not deployed from within a sheath, but rather a distal end portion of a housing of the SPG stimulating device is shaped to define a plurality of electrode arms that are configured to open outward away from a central longitudinal axis of the housing during deployment of the electrode arms. At least one electrode is coupled to each electrode arm such that when the distal end portion is placed within the nose and the electrode arm is deployed, the at least one electrode is positioned to stimulate the SPG.
Alternatively, for some applications, an inflatable SPG stimulating device is a flexible tube configured for placement within the nose and has at least one inflatable electrode mount at a distal end portion of the tube with at least one electrode coupled to the inflatable mount, and an inflation actuator at a proximal end portion of the tube. When the inflatable SPG stimulating device is placed within the nose and the at least one inflatable electrode mount is inflated, the at least one electrode is positioned to stimulate the SPG. Typically, the inflatable SPG stimulating device also includes an inflatable nasal stabilizer configured to stabilize the flexible tube with respect to a nostril of the nose when the flexible tube is disposed within the nose and the inflatable nasal stabilizer is inflated.
There is therefore provided, in accordance with some applications of the present invention, a method for treating a patient in cardiac arrest or in an acute post-cardiac arrest phase, the method including:
For some applications, coupling the electrodes to the tissue includes positioning the electrodes within a nose of the patient such that the electrodes are in position to stimulate the SPG.
For some applications, coupling the electrodes to the tissue includes positioning the electrodes on skin over a mandibular notch of the patient such that the electrodes are in position to stimulate the SPG.
For some applications, coupling the electrodes to the tissue includes positioning the electrodes against gingiva of the patient such that the electrodes are in position to stimulate the SPG.
For some applications, coupling the electrodes to the tissue includes positioning the electrodes against the hard palate of a mouth of the patient such that the electrodes are in position to stimulate the SPG.
For some applications, coupling the electrodes to the tissue includes coupling the electrodes to the tissue within 24 hours of an onset of the cardiac arrest.
For some applications, coupling the electrodes to the tissue includes coupling the electrodes to the tissue within 6 hours of an onset of the cardiac arrest.
For some applications:
For some applications, activating the power source to drive the electrodes to apply current to the SPG after the activation of the defibrillator includes activating the power source to drive the electrodes to apply current to the SPG within 1 hour after the activation of the defibrillator.
There is further provided, in accordance with some applications of the present invention, a medical device including:
There is further provided, in accordance with some applications of the present invention, a sphenopalatine ganglion (SPG) stimulating device for stimulating an SPG of a patient, the device including:
For some applications, the sheath is flexible.
For some applications, the sheath includes silicone.
For some applications, a distance between the nasal stabilizer and the at least one electrode opening is 4-8 cm.
For some applications, an outer diameter of the nasal stabilizer is 3-15 mm greater than an outer diameter of the sheath.
For some applications, an outer diameter of the sheath is 3-8 mm.
For some applications, the device further includes a releasable pre-deployment lock, configured to prevent sliding of the electrode mount within the sheath.
For some applications, the at least one electrode is configured to curve away from a central longitudinal axis of the sheath during deployment of the at least one electrode.
For some applications, the nasal stabilizer is connected to the sheath.
For some applications, the nasal stabilizer is inseparable from the sheath without breaking a portion of the device.
For some applications, the at least one electrode includes a plurality of electrodes.
For some applications, the plurality of electrodes includes exactly three independently-addressable electrodes.
For some applications, the electrode mount further includes a plurality of flexible prongs, and each of the plurality of electrodes is coupled to a respective one of the flexible prongs.
For some applications, the at least one electrode is arranged such that distal motion of the electrode mount with respect to the sheath deploys the at least one electrode out of the sheath through the at least one electrode opening.
For some applications, the nasal stabilizer is arranged to remain in a same location with respect to the sheath during the distal motion of the electrode mount with respect to the sheath.
For some applications, the device further includes a releasable post-deployment lock, configured to prevent sliding of the electrode mount within the sheath following the distal motion of the electrode mount with respect to the sheath.
For some applications, the at least one electrode is arranged such that proximal motion of the sheath with respect to the electrode mount deploys the at least one electrode out of the sheath through the at least one electrode opening.
For some applications, the sheath is arranged to slide proximally with respect to the nasal stabilizer during the proximal motion of the sheath with respect to the electrode mount.
For some applications, the sheath is shaped to define a longitudinal slit on a lateral side of the sheath, and the nasal stabilizer is connected to the electrode mount through the longitudinal slit.
For some applications, the longitudinal slit extends from a distal end of the sheath to a location along the sheath that is proximal to the nasal stabilizer.
For some applications, the longitudinal slit extends from the distal end of the sheath to a proximal end of the sheath.
For some applications, the device further includes an implant handle for stabilizing the electrode mount during the proximal motion of the sheath, the implant handle protruding from the electrode mount through the longitudinal slit at a location along the electrode mount that is proximal to the nasal stabilizer.
For some applications, the device further includes an insulating coating that coats the at least one electrode, the insulating coating leaving at least one exposed region of the at least one electrode configured for driving current into tissue of the patient.
For some applications, the insulating coating leaves a plurality of exposed regions of the at least one electrode for driving current into tissue of the patient.
For some applications, the device further includes a sensor coupled to the sheath and configured to sense a physiological response of the patient to stimulation of the SPG.
For some applications, the sensor is a Doppler flowmetry sensor.
For some applications, the sensor is fixed to the sheath.
For some applications, the device further includes a sensor coupled to the electrode mount and configured to sense a physiological response of the patient to stimulation of the SPG.
For some applications, the sensor is fixed to a lateral side of the electrode mount.
For some applications, the sheath is shaped to define at least one sensor hole, and the sensor fixed to the electrode mount is configured to sense the physiological response of the patient through the sensor hole.
For some applications, the sensor is a Doppler flowmetry sensor.
For some applications, the device further includes a camera coupled to the sheath and configured to facilitate navigation of the sheath toward the SPG.
For some applications, the camera is fixed to the sheath.
For some applications, the device further includes a camera fixed to a distal end of the electrode mount, configured to facilitate navigation of the distal end of the electrode mount toward the SPG.
For some applications, the device further includes a control unit including a battery and circuitry and configured to drive the at least one electrode to stimulate the SPG.
For some applications, the control unit is wearable.
For some applications, the device further includes a mandibular notch electrode coupled to the control unit and couplable to skin over a mandibular notch of the patient, and the control unit is configured to drive the at least one electrode to stimulate the SPG by driving a current between the at least one electrode and the mandibular notch electrode.
For some applications, the device further includes a gingival electrode frame and a gingival electrode mounted on the gingival frame, the gingival electrode coupled to the control unit and couplable, using the gingival electrode frame, to gingiva of the patient, and the control unit is configured to drive the at least one electrode to stimulate the SPG by driving a current between the at least one electrode and the gingival electrode.
For some applications, the device further includes a dental arch electrode frame configured to be mounted to a dental arch of the patient and at least one greater palatine foramen (GPF) electrode coupled to the dental arch electrode frame, the at least one GPF electrode coupled to the control unit and couplable, using the dental arch electrode frame, to a hard palate of the patient over a GPF of the patient, and the control unit is configured to drive the at least one electrode to stimulate the SPG by driving a current between the at least one electrode and the at least one GPF electrode.
For some applications, the device further includes a greater palatine foramen electrode frame and a greater palatine foramen electrode mounted on the greater palatine foramen electrode frame, the greater palatine foramen electrode coupled to the control unit and couplable, using the greater palatine foramen electrode frame, to tissue over a greater palatine foramen of the patient, and the control unit is configured to drive the at least one electrode to stimulate the SPG by driving a current between the at least one electrode and the greater palatine foramen electrode.
For some applications, the device further includes a sensor configured to sense a physiological response of the patient to stimulation of the SPG and to send to the control unit a signal indicative of the physiological response.
For some applications, the at least one electrode includes a plurality of electrodes, and the control unit is configured to designate at least one of the plurality of electrodes to exclude from use for stimulating the SPG in response to the signal.
For some applications, the sensor is a Doppler flowmetry sensor.
For some applications, the Doppler flowmetry sensor is configured to be coupled to skin of the patient over a carotid artery of the patient.
There is further provided, in accordance with some applications of the present invention, a sphenopalatine ganglion (SPG) stimulating device for stimulating an SPG of a patient, the device including:
For some applications, the plurality of electrode arms includes exactly three electrode arms.
There is further provided, in accordance with some applications of the present invention, a sphenopalatine ganglion (SPG) stimulating device for stimulating an SPG of a patient, the device including:
For some applications, the device further includes an inflatable nasal stabilizer disposed around the flexible tube and configured to stabilize the flexible tube with respect to a nostril of the nose when the flexible tube is disposed within the nose and the inflatable nasal stabilizer is inflated.
For some applications, the at least one inflatable electrode mount includes a plurality of inflatable electrode mounts positioned circumferentially around the distal end portion of the flexible tube, and the at least one electrode includes a respective at least one electrode coupled to each of the plurality of inflatable electrode mounts.
For some applications, the plurality of inflatable electrode mounts includes exactly three inflatable electrode mounts.
For some applications, the at least one inflatable electrode mount includes an inflatable electrode balloon, and the at least one electrode includes a plurality of electrodes positioned circumferentially around the inflatable balloon such that when the device is placed within the nose and the inflatable electrode balloon is inflated, at least one of the plurality of electrodes is positioned to stimulate the SPG.
The present invention will be more fully understood from the following detailed description of applications thereof, taken together with the drawings, in which:
Reference is now made to
For clarity of illustration, SPG stimulation is generally shown and described with respect to a single SPG 22. In any of the configurations described herein, the SPG stimulation may be applied to either a single SPG (the left or the right SPG) or both SPGs, in which case many of the elements of the system are duplicated for the left and right sides of the head.
For some applications, such as is shown for example in
Reference is now made to
Reference is now made to
For some applications, a medical device 43 may be used that comprises a defibrillator and an SPG stimulator, for example as shown in
For some applications, alternatively or additionally to increasing CBF to treat a patient in cardiac arrest or in an acute post-cardiac arrest phase, SPG stimulating device 20 may be used for any of the following:
Reference is now made to
Reference is now made to
Typically, sheath 50 is flexible. For example, sheath 50 may be made of a flexible polymer, e.g., silicone. For some applications, dimensions of SPG stimulating device 20 may include one or more of the following:
For some applications, SPG stimulating device 20 has a plurality of electrodes 30, e.g., exactly three independently-addressable electrodes 30. For some applications, electrode mount 62 has a plurality of flexible prongs 64, with each of the plurality of electrodes 30 coupled to a respective one of flexible prongs 64. During deployment of electrode(s) 30, electrode(s) 30 may curve away from a central longitudinal axis 66 of sheath 50, e.g., electrode prong(s) 64 to which electrode(s) 30 are coupled may curve away from central longitudinal axis 66 during deployment of electrode(s) 30 out of sheath 50 (such as is shown in
For some applications, an insulating coating 31 coats electrode(s) 30, the insulating coating leaving at least one exposed region, e.g., a plurality of exposed regions, of electrode(s) 30 configured for driving current into tissue of patient 24. For example, a traditional electrode lead may be used comprising platinum-iridium electrodes that are placed along an insulating lead and are all connected to an inner conductive wire of the lead.
For some applications, SPG stimulating device 20 includes a releasable pre-deployment lock 68 that prevents electrode mount 62 from sliding within sheath 50. This allows SPG stimulating device 20 to be positioned within nose 28 of patient 24 without the medical practitioner needing to worry about electrode mount 62 sliding within sheath 50. Once SPG stimulating device 20 is correctly positioned within nose 28, the medical practitioner can unlock releasable pre-deployment lock 68 and slidably deploy electrode(s) 30, as further described hereinbelow. Releasable pre-deployment lock 68 may be any of kind of lock that holds electrode mount 62 stationary with respect to sheath 50 and can be released to enable electrode mount 62 to slide with respect to sheath 50. For example, releasable pre-deployment lock 68 may include a small hole in sheath 50 and a depressible protrusion on electrode mount 62 configured to protrude from electrode mount 62 in the absence of an external force pushing the protrusion down; in a locked state the protrusion protrudes through the hole in sheath 50 and can be depressed so as to enable electrode mount 62 to slide.
Reference is now made specifically to
For some applications, SPG stimulating device 20′ further includes a releasable post-deployment lock 72 configured to prevent sliding of electrode mount 62 within sheath 50 following the distal motion of electrode mount 62 with respect to sheath 50. This prevents electrode(s) 30 from moving within nose 28 of patient 24 once they have been deployed and are in position to stimulate SPG 22 of patient 24. Releasable post-deployment lock 72 may be the same type of lock as releasable pre-deployment lock 68 or may be a different type of lock. In order to remove SPG stimulating device 20′ from within nose 28 of patient 24, releasable post-deployment lock 72 is released and electrode mount 62 is pulled proximally by proximal end 70 of electrode mount 62 in order to pull electrode(s) 30 back into sheath 50. Releasable pre-deployment lock 68 is then optionally locked again and SPG stimulating device 20′ can be pulled out of nose 28 of patient 24.
Reference is now made specifically to
Reference is now made to
Reference is again made to
Typically, SPG stimulating device 20 includes a camera 90, e.g., a micro camera, or a fiber-optic camera, to facilitate navigation of the device toward SPG 22. For some applications, such as for SPG stimulating device 20′ shown in
Reference is again made to
Reference is now made to
Reference is now made to
Reference is now made to
Reference is now made to
A deployment actuator 132 is configured to actuate the deployment of electrode arms 124, further described hereinbelow. A camera 134, typically housed in a cone-shaped camera housing 136, is (a) disposed at distal end portion 122 of housing 118 prior to the deployment of electrode arms 124 and (b) configured to facilitate navigation of housing 118 toward SPG 22. As further described hereinbelow, proximal motion of camera 134 toward proximal end portion 120 of housing 118 is associated with, e.g., causes, the deployment of electrode arms 124. Coupled to each electrode arm 124 is at least one electrode 30 such that when distal end portion 122 is placed within nose 28 and electrode arm 124 is deployed, at least one electrode 30 is positioned to stimulate SPG 22. It is noted that the same reference number is used for the electrodes coupled to SPG stimulating device 116 as for electrodes coupled to SPG stimulating device 20 to indicate that the same type of electrodes may be used.
For some applications, deployment actuator 132 is a rotatable spool 137 disposed at a longitudinal location along housing 118, e.g., at proximal end portion 120 of housing 118, configured to be rotated using a knob 138. Camera housing 136 is attached to a string 140 that runs longitudinally through housing 118 and is configured to be wrapped around spool 137 when knob 138 is turned in a first direction, indicated by arrow 142. A spring 144 is disposed within housing 118 between camera housing 136 and proximal end portion 120 of housing such that proximal motion of camera housing 136 causes spring 144 to compress. SPG stimulating device 116 is positioned within nose 28 of patient 24 and then the medical practitioner rotates knob 138 so as to wind string 140 around spool 137, illustrated by arrow 142. As string 140 is wound around spool 137, camera housing 136 is pulled proximally, thereby causing spring 144 to compress. Due to the conical shape of camera housing 136, as camera housing 136 moves proximally, camera housing 136 forces electrode arms 124 to deploy outward.
Reference is now made to
Reference is now made specifically to
Inflation actuator 158′ of SPG stimulating device 148′ is in the form of a hand bulb pump. A hollow pumpable bulb 164 is disposed proximal end portion 152 of flexible tube 150. A first duckbill valve 166 allows air from within bulb 164 to enter an air-channel 168 that extends through flexible tube 150 when bulb 164 is squeezed. Air-channel 168 includes ports that allow air from within air-channel 168 to enter each inflatable electrode mount 156′ and inflatable nasal stabilizer 162. As the squeezing of bulb 164 is released, a second duckbill valve 170 allows air from outside the device to enter bulb 164 in order to re-inflate bulb 164. Bulb 164 may thus be pumped one or more times in order to inflate inflatable electrode mounts 156′ and inflatable nasal stabilizer 162.
Reference is now made specifically to
Inflation actuator 158″ of SPG stimulating device 148″ may be a Luer lock valve to which a Luer syringe 174 may be coupled. When Luer syringe 174 is coupled to the Luer lock valve, the valve is opened and gas or liquid may be injected into flexible tube 150 in order to inflate inflatable electrode balloon 156″ and inflatable nasal stabilizer 162. When Luer syringe 174 is disconnected from the Luer lock valve, the valve self-seals. In order to deflate inflatable electrode balloon 156″ and inflatable nasal stabilizer 162, Luer syringe 174 is re-coupled to the Luer lock valve and the injected gas or liquid escapes or is drawn out. For some applications, inflatable electrode balloon 156″ and inflatable nasal stabilizer 162 may be inflated with an injection of contrast fluid. This may aid visualization of the positioning of SPG stimulating device 148″ within nose 28 under fluoroscopy.
Reference is now made to
An electrode-lead channel 200 for electrode leads 98 extends from inflatable electrode balloon 156″ to a lead-exit hole 202 on a lateral side of SPG stimulating device 148′″.
It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.
Number | Name | Date | Kind |
---|---|---|---|
4044774 | Corbin et al. | Aug 1977 | A |
4503863 | Katims | Mar 1985 | A |
5088977 | Sibalis | Feb 1992 | A |
5121754 | Mullett | Jun 1992 | A |
5433739 | Sluijter et al. | Jul 1995 | A |
5529574 | Frackelton | Jun 1996 | A |
5792100 | Shantha | Aug 1998 | A |
5911223 | Weaver et al. | Jun 1999 | A |
5938690 | Law et al. | Aug 1999 | A |
6041252 | Walker et al. | Mar 2000 | A |
6146380 | Racz et al. | Nov 2000 | A |
6161047 | King et al. | Dec 2000 | A |
6360750 | Gerber et al. | Mar 2002 | B1 |
6526318 | Ansarinia | Feb 2003 | B1 |
6567702 | Nekhendzy et al. | May 2003 | B1 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6602248 | Sharps et al. | Aug 2003 | B1 |
6620155 | Underwood et al. | Sep 2003 | B2 |
6941172 | Nachum | Sep 2005 | B2 |
6997941 | Sharkey et al. | Feb 2006 | B2 |
7013177 | Whitehurst et al. | Mar 2006 | B1 |
7117033 | Shalev et al. | Oct 2006 | B2 |
7120489 | Shalev et al. | Oct 2006 | B2 |
7146209 | Gross et al. | Dec 2006 | B2 |
7217351 | Krumme | May 2007 | B2 |
7223227 | Pflueger | May 2007 | B2 |
7270659 | Ricart et al. | Sep 2007 | B2 |
7317947 | Wahlstrand et al. | Jan 2008 | B2 |
7398121 | Matsumura et al. | Jul 2008 | B2 |
7509171 | DiMauro | Mar 2009 | B2 |
7561919 | Shalev et al. | Jul 2009 | B2 |
7636597 | Gross et al. | Dec 2009 | B2 |
7640062 | Shalev | Dec 2009 | B2 |
7684859 | Shalev et al. | Mar 2010 | B2 |
7818063 | Wallace et al. | Oct 2010 | B2 |
7831306 | Finch et al. | Nov 2010 | B2 |
7860569 | Solberg et al. | Dec 2010 | B2 |
8055347 | Lamensdorf et al. | Nov 2011 | B2 |
8060207 | Wallace et al. | Nov 2011 | B2 |
8103350 | Wallace et al. | Jan 2012 | B2 |
8190248 | Besio et al. | May 2012 | B2 |
8287902 | Gross | Oct 2012 | B2 |
8353853 | Kyle et al. | Jan 2013 | B1 |
8457761 | Wariar | Jun 2013 | B2 |
8494641 | Boling et al. | Jul 2013 | B2 |
8577469 | Gross | Nov 2013 | B2 |
8676348 | Gross | Mar 2014 | B2 |
8731674 | Wallace et al. | May 2014 | B2 |
8954149 | Shalev | Feb 2015 | B2 |
9233245 | Lamensdorf et al. | Jan 2016 | B2 |
9433774 | Dar et al. | Sep 2016 | B2 |
9616221 | Gross | Apr 2017 | B2 |
9675796 | Dayan et al. | Jun 2017 | B2 |
9724513 | Lane et al. | Aug 2017 | B2 |
9724515 | Fostick et al. | Aug 2017 | B2 |
9731122 | Gross | Aug 2017 | B2 |
9775996 | Gross | Oct 2017 | B2 |
10271907 | Dayan et al. | Apr 2019 | B2 |
10279192 | Malchano et al. | May 2019 | B2 |
10293177 | Malchano et al. | May 2019 | B2 |
10307611 | Malchano et al. | Jun 2019 | B2 |
10398884 | Lad et al. | Sep 2019 | B2 |
10532204 | Gross | Jan 2020 | B2 |
10569086 | Fostick et al. | Feb 2020 | B2 |
10695557 | Townley et al. | Jun 2020 | B1 |
10758722 | Gross et al. | Sep 2020 | B2 |
10881858 | Gross et al. | Jan 2021 | B1 |
10898716 | Fostick et al. | Jan 2021 | B2 |
10994132 | Heldman et al. | May 2021 | B1 |
11027117 | Dar et al. | Jun 2021 | B2 |
11154710 | Belson et al. | Oct 2021 | B2 |
11202905 | Tendler et al. | Dec 2021 | B2 |
11376422 | Gross | Jul 2022 | B2 |
11413455 | Gross | Aug 2022 | B1 |
20020151948 | King et al. | Oct 2002 | A1 |
20020183683 | Lerner | Dec 2002 | A1 |
20030130707 | Gan et al. | Jul 2003 | A1 |
20030158589 | Katsnelson | Aug 2003 | A1 |
20030216792 | Levin et al. | Nov 2003 | A1 |
20030225331 | Diederich et al. | Dec 2003 | A1 |
20040002746 | Ryan et al. | Jan 2004 | A1 |
20040015068 | Shalev et al. | Jan 2004 | A1 |
20040019381 | Pflueger | Jan 2004 | A1 |
20040049134 | Tosaya et al. | Mar 2004 | A1 |
20040049180 | Sharps et al. | Mar 2004 | A1 |
20040116977 | Finch et al. | Jun 2004 | A1 |
20040210209 | Yeung et al. | Oct 2004 | A1 |
20040253304 | Gross et al. | Dec 2004 | A1 |
20050010205 | Hovda et al. | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050119650 | Sanders et al. | Jun 2005 | A1 |
20050137646 | Wallace et al. | Jun 2005 | A1 |
20050137647 | Wallace et al. | Jun 2005 | A1 |
20050159790 | Shalev | Jul 2005 | A1 |
20050187589 | Wallace et al. | Aug 2005 | A1 |
20050203599 | Garabedian et al. | Sep 2005 | A1 |
20050203600 | Wallace et al. | Sep 2005 | A1 |
20050203602 | Wallace et al. | Sep 2005 | A1 |
20050222647 | Wahlstrand et al. | Oct 2005 | A1 |
20050266099 | Shalev | Dec 2005 | A1 |
20050277996 | Podhajsky et al. | Dec 2005 | A1 |
20060030895 | Simon et al. | Feb 2006 | A1 |
20060095066 | Chang | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060224223 | Podhajsky et al. | Oct 2006 | A1 |
20060293723 | Whitehurst et al. | Dec 2006 | A1 |
20070000784 | Paul et al. | Jan 2007 | A1 |
20070073402 | Vresilovic et al. | Mar 2007 | A1 |
20070162086 | Dilorenzo | Jul 2007 | A1 |
20070213700 | Davison et al. | Sep 2007 | A1 |
20070233202 | Wallace et al. | Oct 2007 | A1 |
20070255338 | Wahlstrand | Nov 2007 | A1 |
20080009927 | Vilims | Jan 2008 | A1 |
20080033503 | Fowler et al. | Feb 2008 | A1 |
20080119907 | Stahmann | May 2008 | A1 |
20080260542 | Nishikawa et al. | Oct 2008 | A1 |
20080275430 | Belsky et al. | Nov 2008 | A1 |
20090112278 | Wingeier et al. | Apr 2009 | A1 |
20090125080 | Montgomery | May 2009 | A1 |
20090126813 | Yanagisawa et al. | May 2009 | A1 |
20090131850 | Geiger | May 2009 | A1 |
20090210026 | Solberg et al. | Aug 2009 | A1 |
20090299418 | Shalev et al. | Dec 2009 | A1 |
20090312816 | Gross | Dec 2009 | A1 |
20100114184 | Degtyar et al. | May 2010 | A1 |
20100185258 | Papay | Jul 2010 | A1 |
20100217369 | Gross | Aug 2010 | A1 |
20100324441 | Hargrove et al. | Dec 2010 | A1 |
20110046540 | Alterman et al. | Feb 2011 | A1 |
20110054518 | Carbunaru et al. | Mar 2011 | A1 |
20110160638 | Mauge et al. | Jun 2011 | A1 |
20110160797 | Makous et al. | Jun 2011 | A1 |
20120053659 | Molnar et al. | Mar 2012 | A1 |
20120071811 | Ansarinia | Mar 2012 | A1 |
20120203307 | Schroeppel et al. | Aug 2012 | A1 |
20120323214 | Shantha | Dec 2012 | A1 |
20130066392 | Simon et al. | Mar 2013 | A1 |
20130102952 | Gross | Apr 2013 | A1 |
20130150653 | Borsody | Jun 2013 | A1 |
20130166006 | Williams | Jun 2013 | A1 |
20130184803 | Altman | Jul 2013 | A1 |
20130289385 | Lozano et al. | Oct 2013 | A1 |
20140058189 | Stubbeman | Feb 2014 | A1 |
20140088672 | Bedenbaugh | Mar 2014 | A1 |
20140207224 | Simon | Jul 2014 | A1 |
20140257168 | Gill | Sep 2014 | A1 |
20140324128 | Gross | Oct 2014 | A1 |
20150011927 | Hua | Jan 2015 | A1 |
20150038948 | Ludvig et al. | Feb 2015 | A1 |
20150119898 | Desalles et al. | Apr 2015 | A1 |
20150174406 | Lamensdorf et al. | Jun 2015 | A1 |
20160331970 | Lozano | Nov 2016 | A1 |
20170007823 | Gross | Jan 2017 | A1 |
20170056642 | Moffitt et al. | Mar 2017 | A1 |
20170120053 | Fostick et al. | May 2017 | A1 |
20170182317 | Gross et al. | Jun 2017 | A1 |
20170296121 | Dar et al. | Oct 2017 | A1 |
20170296821 | Fostick et al. | Oct 2017 | A1 |
20180071523 | Gross et al. | Mar 2018 | A1 |
20180132947 | Dayan et al. | May 2018 | A1 |
20180193633 | Gross | Jul 2018 | A1 |
20180193646 | Fostick et al. | Jul 2018 | A1 |
20180318575 | Gross et al. | Nov 2018 | A1 |
20190009076 | Dayan et al. | Jan 2019 | A1 |
20190076653 | Fostick et al. | Mar 2019 | A1 |
20190282807 | Tendler et al. | Sep 2019 | A1 |
20190290908 | Hsu et al. | Sep 2019 | A1 |
20200100838 | Townley et al. | Apr 2020 | A1 |
20200171283 | Tal et al. | Jun 2020 | A1 |
20200222729 | Gertner et al. | Jul 2020 | A1 |
20200297238 | Tsui | Sep 2020 | A1 |
20220008746 | Malchano et al. | Jan 2022 | A1 |
20220288383 | Dar et al. | Sep 2022 | A1 |
20220331594 | Gross et al. | Oct 2022 | A1 |
20230022546 | Malchano et al. | Jan 2023 | A1 |
20230104621 | Malchano et al. | Apr 2023 | A1 |
20230111776 | Malchano et al. | Apr 2023 | A1 |
20230166072 | Malchano et al. | Jun 2023 | A1 |
20230233858 | Minar et al. | Jul 2023 | A1 |
20230381508 | Ludwig et al. | Nov 2023 | A1 |
Number | Date | Country |
---|---|---|
2004-321242 | Nov 2004 | JP |
2007-501067 | Jan 2007 | JP |
9405369 | Mar 1994 | WO |
0152931 | Jul 2001 | WO |
0185027 | Nov 2001 | WO |
2001085094 | Nov 2001 | WO |
2004044947 | May 2004 | WO |
2004045242 | May 2004 | WO |
2005011805 | Feb 2005 | WO |
2005030025 | Apr 2005 | WO |
2005030118 | Apr 2005 | WO |
2006090397 | Aug 2006 | WO |
2008007369 | Jan 2008 | WO |
2009137683 | Nov 2009 | WO |
2017006327 | Jan 2017 | WO |
2017072769 | May 2017 | WO |
2017115351 | Jul 2017 | WO |
2018051338 | Mar 2018 | WO |
2019175879 | Sep 2019 | WO |
2022056310 | Mar 2022 | WO |
2023225265 | Nov 2023 | WO |
Entry |
---|
United States Office Action issued Dec. 13, 2023 in U.S. Appl. No. 18/229,379. |
United States Office Action issued Feb. 15, 2024 in U.S. Appl. No. 18/229,379. |
Karran September E et201 al., 1 “The Amyloid cascade hypothesis for AD,” Nature Reviews Drug Discovery, vol. 10; 698-712. |
De La Torre JC, “Vascular Basis of Alzheimer's Pathogensis,” Ann NY Acad Sci. 977:196-215 (Nov. 2002). |
Weller RO et al, “Perivascular Drainage of Amyloid-b Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease,” Brain Pathology 18 (Apr. 2008) 253-266. |
Brief PubMed search for metal ions in Alzheimers. |
An Office Action dated Sep. 27, 2016, which issued during the prosecution of U.S. Appl. No. 14/926,705. |
U.S. Appl. No. 62/642,663, filed Mar. 14, 2018. |
An International Search Report and a Written Opinion both dated Aug. 7, 2008, which issued during the prosecution of Applicant's PCT/IL2007/000865. |
An Office Action dated Mar. 29, 2013, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
An Office Action dated Oct. 31, 2011, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
An Office Action dated Oct. 1, 2012, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
Notice of Allowance dated Jul. 24, 2013, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
An Office Action dated Apr. 11, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,757. |
Notice of Allowance dated Oct. 28, 2013, which issued during the prosecution of U.S. Appl. No. 13/663,757. |
Elixmann IM et al., “In-vitro evaluation of a drainage catheter with integrated bioimpedance electrodes to determine ventricular size,” Biomed Tech 2013; 58 (Suppl. 1) Sep. 2013 (2 pages total). |
An Office Action dated Aug. 31, 2015, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
An Applicant Initiated Interview Summary dated Dec. 14, 2015, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
An Office Action dated Feb. 3, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
Notice of Allowance dated Dec. 9, 2016, which issued during the prosecution of U.S. Appl. No. 14/794,739. |
An Applicant Initiated Interview Summary dated Feb. 25, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
An Office Action dated Jun. 15, 2016, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
An International Search Report and a Written Opinion both dated Oct. 20, 2016, which issued during the prosecution of Applicant's PCT/IL2016/050728. |
An Office Action dated Sep. 21, 2016, which issued during the prosecution of U.S. Appl. No. 14/794,739. |
An International Search Report and a Written Opinion both dated Jan. 26, 2017, which issued during the prosecution of Applicant's PCT/IL2016/051161. |
Notice of Allowance dated Jul. 14, 2017, which issued during the prosecution of U.S. Appl. No. 13/872,794. |
An Office Action dated May 26, 2017, which issued during the prosecution of U.S. Appl. No. 15/453,290. |
An International Preliminary Report on Patentability dated Apr. 7, 2009, which issued during the prosecution of Applicant's PCT/IL2007/000865. |
Loutzenhiser, “Membrane Potential measurements in renal afferent and efferent arterioles: actions of Angiotensin II”, AJP—Renal Physiol Aug. 1, 1997 vol. 273 No. 2 F307-F314. |
U.S. Appl. No. 60/830,717, filed Jul. 12, 2006. |
Dao-Sheng Liu et al., “Activation of Na+ and K+ Pumping Modes of (Na,K)-ATPase by an Oscillating Electric Field,” The Journal of Biological Chemistry, vol. 265. No. 13, May 5, 1990. (pp. 7260-7267). |
Robert F. Service.. “Electric fields deliver drugs into tumors.” http://news.sciencemaa.ora. Feb. 4, 2015. (5 Pages Total). |
Vernengo J, “Injectable Bioadhesive Hydrogels for Nucleus Pulposus Replacement and Repair of the Damaged Intervertebral Disc: A Thesis,” Drexel University (Jan. 2007). |
Urban JPG et al., “The nucleus of the intervertebral disc from development to degeneration,” American Zoologist 40(1): 53-61 (2000). |
Cheung KMC et al., “Intervertebral disc regeneration by use of autologous mesenchymal stem cells, an experimental model in rabbits,” Abstract from the SRS 2004 Annual Meeting. |
Freemont TJ et al., “Degeneration of intervertebral discs: current understanding of cellular and molecular events, and implications for novel therapies,” Expert Reviews in Molecular Biology, Mar. 29, 2001 (Cambridge University Press). |
An Office Action dated Sep. 12, 2011, which issued during the prosecution of U.S. Appl. No. 12/373,306. |
An Office Action dated Jul. 24, 2017, which issued during the prosecution of U.S. Appl. No. 14/982,187. |
An International Search Report and a Written Opinion both dated Mar. 10, 2017, which issued during the prosecution of Applicant's PCT/IL2016/051363. |
An Office Action dated Apr. 25, 2018, which issued during the prosecution of U.S. Appl. No. 15/637,330. |
U.S. Appl. No. 62/444,939, filed Jan. 11, 2017. |
An Office Action dated Jul. 10, 2019, which issued during the prosecution of U.S. Appl. No. 15/864,065. |
An International Search Report and a Written Opinion both dated May 23, 2019, which issued during the prosecution of Applicant's PCT/IL2019/050284. |
An Office Action dated Mar. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/742,245. |
Borlase NM, “The thalamus in Parkinson's Disease,” Department of Psychology, University of Canterbury, 2012. |
Fernandes J, “Protein May Prevent Neuron Death in Huntington's Patients, Study Finds,” huntingtonsdiseasenews.com, Jan. 19, 2017. |
Lee H-J, “Extracellular asynuclein a novel and crucial factor in Lewy body diseases,” Nat. Rev. Neurol. 10, 92-98 (Feb. 2014); published online Jan. 28, 2014. |
Starr PA et al., “Parkinson's Disease FAQ—Deep Brain Stimulation for Parkinson's Disease,” UCSF Apr. 19, 2017. |
Perez RG et al., “A Role for Alpha-Synuclein in the Regulation of Dopamine Biosynthesis,” The Journal of Neuroscience, Apr. 15, 2002, 22(8):3090-3099. |
Breydo L et al., “α-Synuclein misfolding and Parkinson's disease,” Biochimica et Biophysica Acta 1822 (2012) 261-285 (Available online Oct. 12, 2011). |
Deleidi M et al., “Protein Clearance Mechanisms of Alpha-Synuclein and Amyloid-Beta in Lewy Body Disorders,” International Journal of Alzheimer's Disease, vol. 2012. |
Xie L et al., “Sleep Drives Metabolite Clearance from the Adult Brain,” Science. Oct. 18, 2013; 342(6156). |
Valdinocci D et al., “Potential Modes of Intercellular α-Synuclein Transmission,” International Journal of Molecular Sciences, Feb. 22, 2017. |
U.S. Appl. No. 62/500,747, filed May 3, 2017. |
An Office Action dated Jul. 29, 2019, which issued during the prosecution of U.S. Appl. No. 15/618,325. |
Sawyer, P N et al. “Measurement of streaming potentials of mammalian blood vessels, aorta and vena cava, in vivo.” Biophysical journal vol. 6,5 (1966): 641-51. doi:10.1016/50006-3495(66)86683-3, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1368020/, viewed on Jul. 22, 2019. |
An Office Action dated Nov. 29, 2019, which issued during the prosecution of U.S. Appl. No. 15/969,411. |
An Office Action dated Jan. 7, 2020, which issued during the prosecution of U.S. Appl. No. 15/618,325. |
An Office Action dated Jan. 7, 2020, which issued during the prosecution of European Patent Application No. 16741703.9. |
An Office Action dated Jan. 22, 2020, which issued during the prosecution of U.S. Appl. No. 15/771,551. |
An Office Action dated Mar. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/618,325. |
An Office Action together with the English Translation dated Aug. 19, 2020, which issued during the prosecution of Japanese Patent Application No. 2018-521586. |
An Office Action dated Mar. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/574,772. |
An Office Action dated Nov. 20, 2020, which issued during the prosecution of U.S. Appl. No. 16/353,407. |
An International Search Report and a Written Opinion both dated Dec. 20, 2020, which issued during the prosecution of Applicant's PCT/IL2020/051022. |
An Office Action dated Nov. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/713,660. |
An Office Action dated Nov. 15, 2021, which issued during the prosecution of U.S. Appl. No. 16/692,528. |
A Notice of Allowance dated Apr. 27, 2022, which issued during the prosecution of U.S. Appl. No. 17/667,051. |
A Non-Final Office Action issued in U.S. Appl. No. 17/828,109, dated Apr. 12, 2023. |
Austin SA, Santhanam AV, Hinton DJ, Choi DS, Katusic ZS. Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J Neurochem. Dec. 2013;127(5):691-700. doi: 10.1111/jnc.12334. Epub Jun. 27, 2013. PMID: 23745722; PMCID: PMC3825764. |
Baker TS, Robeny J, Cruz D, Bruhat A, Iloreta AM, Costa A, Oxley TJ. Stimulating the Facial Nerve to Treat Ischemic Stroke: A Systematic Review. Front Neurol. Nov. 18, 2021;12:753182. |
Benussi A, Cantoni V, Cotelli MS, Cotelli M, Brattini C, Datta A, Thomas C, Santarnecchi E, Pascual-Leone A, Borroni B. Exposure to gamma tACS in Alzheimer's disease: A randomized, double-blind, sham-controlled, crossover, pilot study. Brain Stimul. May-Jun. 2021;14(3):531-540. doi: 10.1016/j.brs.2021.03.007. Epub Mar. 21, 2021. PMID: 33762220. |
Chen J, Wang Z, Chen Q, Fu Y, Zheng K. Transcranial Direct Current Stimulation Enhances Cognitive Function in Patients with Mild Cognitive Impairment and Early/Mid Alzheimer's Disease: A Systematic Review and Meta-Analysis. Brain Sci. Apr. 27, 2022;12(5):562. |
Dhaynaut M, Sprugnoli G, Cappon D, Macone J, Sanchez JS, Normandin MD, Guehl NJ, Koch G, Paciorek R, Connor A, Press D, Johnson K, Pascual-Leone A, El Fakhri G, Santarnecchi E. Impact of 40 Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series. J Alzheimers Dis. 2022;85(4):1667-1676. doi: 10.3233/JAD-215072. PMID: 34958021; PMCID: PMC9023125. |
Grossman N, Bono D, Dedic N, Kodandaramaiah SB, Rudenko A, Suk HJ, Cassara AM, Neufeld E, Kuster N, Tsai LH, Pascual-Leone A, Boyden ES. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. Cell. Jun. 1, 2017;169(6):1029-1041.e16. |
Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. Dec. 7, 2016;540(7632):230-235. doi: 10.1038/nature20587. Erratum in: Nature. Oct. 2018;562(7725):E1. PMID: 27929004; PMCID: PMC5656389. |
Iturria-Medina, Y., Sotero, R., Toussaint, P et al. Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun 7, 11934 (2016). |
Jamali S, Ross B. Sustained changes in somatosensory gamma responses after brief vibrotactile stimulation. Neuroreport. May 7, 2014;25(7):537-41. |
Khedr EM, Salama RH, Abdel Hameed M, Abo Elfetoh N, Seif P. Therapeutic Role of Transcranial Direct Current Stimulation in Alzheimer Disease Patients: Double-Blind, Placebo-Controlled Clinical Trial. Neurorehabil Neural Repair. May 2019;33(5):384-394. |
Levi H, Schoknecht K, Prager O, Chassidim Y, Weissberg I, Serlin Y, Friedman A. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model. PLoS One. 2012;7(6):e39636. doi: 10.1371/journal.pone.0039636. Epub Jun. 22, 2012. PMID: 22745798; PMCID: PMC3382129. |
Liu Y, Liu S, Tang C, Tang K, Liu D, Chen M, Mao Z, Xia X. Transcranial alternating current stimulation combined with sound stimulation improves cognitive function in patients with Alzheimer's disease: Study protocol for a randomized controlled trial. Front Aging Neurosci. Jan. 9, 2023;14:1068175. |
Liu Y, Tang C, Wei K, Liu D, Tang K, Chen M, Xia X, Mao Z. Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: A case report and literature review. Front Neurol. Sep. 23, 2022;13:962684. |
Luo Y, Yang H, Yan X, Wu Y, Wei G, Wu X, Tian X, Xiong Y, Wu G, Wen H. Transcranial Direct Current Stimulation Alleviates Neurovascular Unit Dysfunction in Mice With Preclinical Alzheimer's Disease. Front Aging Neurosci. Apr. 14, 2022;14:857415. |
Manippa V, Palmisano A, Nitsche MA, Filardi M, Vilella D, Logroscino G, Rivolta D. Cognitive and Neuropathophysiological Outcomes of Gamma-tACS in Dementia: A Systematic Review. Neuropsychol Rev. Mar. 6, 2023. doi: 10.1007/s11065-023-09589-0. Epub ahead of print. |
Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. Apr. 4, 2019;177(2):256-271.e22. |
McDermott B, Porter E, Hughes D, McGinley B, Lang M, O'Halloran M, Jones M. Gamma Band Neural Stimulation in Humans and the Promise of a New Modality to Prevent and Treat Alzheimer's Disease. J Alzheimers Dis. 2018;65(2):363-392. |
Saver JL, Kharaishvili N, Janelidze T, Beridze M, Zarqua N, Solberg Y, Bornstein NM; IMPACT-24M Trial Investigators. Refined Sphenopalatine Ganglion Stimulator Placement and Intensity Setting to Augment Blood Flow and Neurologic Function. Stroke. Dec. 2019;50(12):3512-3518. |
Suk HJ, Buie N, Xu G, Banerjee A, Boyden ES, Tsai LH. Vibrotactile stimulation at gamma frequency mitigates pathology related to neurodegeneration and improves motor function. Front Aging Neurosci. May 18, 2023;15:1129510. |
Talman WT, Nitschke Dragon D. Neuronal nitric oxide mediates cerebral vasodilatation during acute hypertension. Brain Res. Mar. 30, 2007;1139:126-32. doi: 10.1016/j.brainres.2007.01.008. Epub Jan. 8, 2007. |
Wu L, Cao T, Li S, Yuan Y, Zhang W, Huang L, Cai C, Fan L, Li L, Wang J, Liu T, Wang J. Long-term gamma transcranial alternating current stimulation improves the memory function of mice with Alzheimer's disease. Front Aging Neurosci. Sep. 15, 2022;14:980636. |
Sangjun Lee, “Individually customized transcranial temporal interference stimulation for focused modulation of deep brain structures: a simulation study with different head models”, Scientific Reports, 2020, vol. 10, No. 11730 (11 pages total). |
United States Office Action issued Dec. 6, 2023 in U.S. Appl. No. 18/351,247. |
“Sphenopalatine Ganglion (SPG) Block (Injection Technique),” DFW Pain Institute, PLLC DBA NorTex Spine & Joint Institute, https://www.nortexspineandjoint.com/sphenopalatine-ganglion-block/, Reviewed Jan. 30, 2023. |